Table I.
Clinical characteristics of ATL patients according to SWDI for the IgG heavy‐chain repertoire in PBMC.
| Characteristics | SWDI for IgG heavy‐chain repertoire in PBMC | P value | |
|---|---|---|---|
| <5·38 | >5·38 | ||
| Number (%) | 44 (54) | 37 (46) | |
| Age (year) | 0·958 | ||
| Mean | 68 | 69 | |
| Median | 69 | 68 | |
| Range | 41–86 | 41–83 | |
| Previous systemic chemotherapy | 0·579 | ||
| Yes | 10 (23) | 6 (16) | |
| No | 34 (77) | 31 (84) | |
| Sex | 0·252 | ||
| Female | 30 (68) | 20 (54) | |
| Male | 14 (32) | 17 (46) | |
| Clinical subtype | 1·000 | ||
| Chronic, smouldering | 7 (16) | 6 (16) | |
| Acute, lymphoma | 37 (84) | 31 (84) | |
| ECOG PS | 0·323 | ||
| 0, 1 | 29 (66) | 29 (78) | |
| 2, 3, 4 | 15 (34) | 8 (22) | |
| Serum sIL‐2R (U/ml) | 0·278 | ||
| <20 000 | 37 (84) | 27 (73) | |
| >20 000 | 7 (16) | 10 (27) | |
| Serum Ca (mg/dl)*,† | 0·655 | ||
| <11·0 | 41 (95) | 33 (92) | |
| >11·0 | 2 (5) | 3 (8) | |
| Serum albumin (g/dl)* | 0·643 | ||
| >3·5 | 26 (79) | 24 (67) | |
| <3·5 | 17 (21) | 12 (33) | |
| HTLV‐1 PVL (copies/1 000 PBMC) | 0·090 | ||
| Mean | 571·6 | 379·2 | |
| Median | 458·6 | 219·9 | |
| Range | 0·8–3 093·7 | 0·5–1 919·5 | |
Alb, albumin; ATL, adult T‐cell leukaemia–lymphoma; Ca, calcium; ECOG, Eastern Cooperative Oncology Group; IgG, immunoglobulin G; PBMC, peripheral blood mononuclear cells; PS, performance status; sIL‐2R, soluble interleukin‐2 receptor; SWDI, Shannon–Weaver diversity index.
*
The data of two patients were unknown.
†
When serum Alb level was less than 4·0 g/dl, serum Ca was adjusted by the concentration of serum Alb as follows: adjusted Ca level (mg/dl) = measured Ca level (mg/dl) + [4‐albumin level (g/dl)]. HTLV‐1, human T cell lymphotropic virus type 1; PVL, provirus load.